Researcher
Debby Thomas
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Jun 2017 → 30 Sep 2022 - Gynaecological Oncology (Division)
Member
From1 Mar 2014 → 31 May 2017 - Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) (Division)
Member
From1 Mar 2010 → 28 Feb 2014
Projects
1 - 2 of 2
- Symmetric antibodies for symmetric epitopes: development and validation of the Symbody platform.From1 Oct 2021 → TodayFunding: IOF - technology validation in lab
- Deciphering Tau structure and oligomerization propensities: Towards innovative therapeutics, prognostics and diagnosticsFrom1 Jan 2021 → 31 Dec 2023Funding: IOF - technology validation in lab
Publications
1 - 10 of 49
- Combined deficient response to polysaccharide-based and protein-based vaccines predicts a severe clinical phenotype(2024)
Authors: Rik Schrijvers, Debby Thomas, Giorgia Bucciol, Isabelle Meyts, Xavier Bossuyt
Pages: 138 - 149 - Identifying risk factors of anti-TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease(2024)
Authors: Karen van Hoeve, Debby Thomas, Ilse Hoffman, Erwin Dreesen
Pages: 95 - 104 - Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment.(2023)
Authors: Debby Thomas, Séverine Vermeire
- A yeast-based model to study the structural properties of the neurodegenerative disease-related protein Tau(2023)
Authors: Joke Verelst, Sander Govers, Debby Thomas, Joris Winderickx
- A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases(2023)
Authors: Wannee Kantasiripitak, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
Pages: 896 - 908 - Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn?s disease(2023)
Authors: Debby Thomas
Pages: 366 - 372 - Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease(2023)
Authors: Bram Verstockt, Séverine Vermeire, Debby Thomas, Paul Declerck
Pages: 838 - + - Model-informed precision dosing of infliximab to improve outcomes of individual patients with inflammatory bowel diseases(2023)
Authors: Wannee Kantasiripitak, Erwin Dreesen, Marc Ferrante, Debby Thomas
- Detection of Breast Cancer-Specific Extracellular Vesicles with Fiber-Optic SPR Biosensor(2023)
Authors: Yagmur Yildizhan, Debby Thomas, Nick Geukens, Jeroen Lammertyn, Dragana Spasic
- Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease(2023)
Authors: Nathalie Van den Berghe, Dahham Alsoud, Bram Verstockt, Séverine Vermeire, Paul Declerck, Debby Thomas